Redhill Biopharma Ltd. (RDHL) Social Stream

Featured Post From StockTwits About RDHL

$RDHL So the global 475-patient study is completed as we know. 57 study locations in 10 countries:

UK, Russia, UK, Brazil, Peru, Italy, Mexico, Israel, Poland, Colombia.

I wonder what is the % of different covid variants among those patients? I certain that opaganib wll prove to be effective, what I wonder is, will this P3 be able to showcase efficacy against all concerning variants.

As we do not know how many Delta or Lambda or Colombian variants are there among those 475 patients I guess we can just wait for the results. I think at least Delta (UK, US, Russia) and Lambda (Peru, Colombia, Mexico) should be well covered by this study. Any thoughts on this?